Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib

PURPOSE: Although patients with unresectable or metastatic melanoma can experience long-term survival with BRAF- and MEK-targeted agents or immune checkpoint inhibitors over 5 years, resistance develops in most patients. There is a distinct lack of pretherapeutic biomarkers to identify which patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Brase, Jan C., Walter, Robert F.H., Savchenko, Alexander, Gusenleitner, Daniel, Garrett, James, Schimming, Tobias, Varaljai, Renata, Castelletti, Deborah, Kim, Ju, Dakappagari, Naveen, Schultz, Ken, Robert, Caroline, Long, Georgina V., Nathan, Paul D., Ribas, Antoni, Flaherty, Keith T., Karaszewska, Boguslawa, Schachter, Jacob, Sucker, Antje, Schmid, Kurt W., Zimmer, Lisa, Livingstone, Elisabeth, Gasal, Eduard, Schadendorf, Dirk, Roesch, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401540/
https://www.ncbi.nlm.nih.gov/pubmed/34108180
http://dx.doi.org/10.1158/1078-0432.CCR-20-3586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401540/
https://www.ncbi.nlm.nih.gov/pubmed/34108180
http://dx.doi.org/10.1158/1078-0432.CCR-20-3586

Ejemplares similares